News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Takeda Pharmaceutical Co. Ltd. (TKPYY) CEO Fesses Up To Blopress Mis-Marketing


3/4/2014 7:33:15 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Takeda's chief executive Yasuchika Hasegawa has admitted the company may have used "inappropriate" language in its marketing of blood pressure blockbuster Blopress, but denied any data falsification. Hasegawa told the Wall Street Journal that the company had used a graph in promotional literature indicating Blopress (candesartan cilexetil) was more effective than rival blood pressure drug Norvasc (amlodipine) from Pfizer which was not supported by clinical data. Blopress - also sold as Atacand - was a big seller for Takeda for many years, with sales approaching $2bn before it lost patent protection in 2012.

Help employers find you! Check out all the jobs and post your resume.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES